US IPO Pipeline SEC S-1 Filings — May 12, 2026

Net loss narrowed 17.9% YoY to $3.617M in FY2025 from $4.403M in FY2024, outperforming Sunshine's cash dependency and Tidewise's lack of ops, indicating relative operational improvement

Pro forma cash to increase 55% to $14.16M from $9.12M post-$5M offering (Dec 31, 2025 base), providing liquidity buffer vs Amesite's going concern cash shortfall

Clean SPAC structure with $10/unit IPO and detailed pro forma dilution scenarios (no redemption to 100%, over-allotment variants as of Oct 31, 2025), standard for de-SPAC upside potential

5.435M shares outstanding as of May 1, 2026, low float ahead of IPO supports potential post-listing momentum vs Sunshine's high warrant overhang

Dr. Steve N. Slilaty beneficially owns 100% Series B Preferred (1,000 votes/share), signaling strong management conviction/alignment unlike neutral Tidewise

FY2025 10-K and QEs (Sep 30/Dec 31, 2025) provide recent operational visibility, contrasting Tidewise's pre-revenue blank-check status

Excludes 15.2M Series B Warrants at $2.07 exercise from offering, preserving upside leverage vs Amesite's unlisted warrants

Filing effective dates Jan 30/31, 2026, indicate accelerated IPO timeline vs peers' May 12 filings, potential first-mover in SPAC wave

NurseMagic AI healthcare software progress amid risks, positions as AI outlier with loss improvement vs sector cash burns

Best-efforts $5M raise at $1.03/unit (near current Nasdaq price) avoids deep discount vs typical distressed offerings

Substantial doubt on viability with insufficient cash for next 12 months; management plans equity raises unassured, worse than Sunshine's pro forma cash boost

Nasdaq bid price < $1.00 risk (recent prices above/below), no minimum offering proceeds, full discretion use heightens failure odds

Multiple redemption scenarios up to 100% of maximum with forfeited shares if no over-allotment (pro forma Oct 31, 2025), standard SPAC erosion

Speculative Series C Warrants at $1.03 exercise + 15.2M Series B at $2.07 overhang, plus 482/400 shares at $220/$4,000, massive dilution potential

Extensive risks for NurseMagic compliance, cybersecurity, key personnel dependency, competitive AI pressures exceed Tidewise's blank-check simplicity

100% Series B Pref ownership by Dr. Slilaty (1,000 votes/share) concentrates power, potential for misaligned decisions vs diversified Amesite

FY2025 loss $3.617M despite 17.9% YoY improvement still signals ongoing burn, no revenue trends vs Sunshine's cash position

Zero operational data or period comparisons as pre-IPO SPAC, fully reliant on future de-SPAC vs Amesite's narrowing losses

17.9% YoY net loss reduction to $3.617M positions for AI healthcare IPO alpha if financing succeeds, undervalued vs delisting-threatened Sunshine

$5M raise boosts cash 55% to $14.16M pro forma, opportunity to stabilize Nasdaq bid price >$1.00 and fund growth

$10/unit launch with dilution scenarios offers de-SPAC arbitrage if healthcare/AI target (synergy with peers), low entry vs operational risks

5.435M shares as of May 1, 2026, pre-IPO scarcity could drive post-listing squeeze, outperforming Sunshine's warrant dilution

Excluded high-exercise Series B Warrants ($2.07) + Series C at $1.03 provide cheap leverage if stock rebounds from delist risk

Effective dates Jan 30/31, 2026, enable fast IPO vs May 12 peers, capture SPAC resurgence in biotech/AI

Leverage FY2025 10-K + QEs (Sep/Dec 2025) for deep dive into AI metrics, potential short squeeze on going concern resolution

100% Series B ownership by CEO aligns for aggressive turnaround, buy opportunity near $1.03 vs Amesite uncertainty

2/3 filings (Sunshine, Amesite) mixed sentiment with delisting/going concern risks, contrasting Tidewise neutral; implies biotech/AI funding crunch, favor SPACs for lower entry risks

Amesite sole YoY improvement (17.9% net loss reduction FY2025), absent in pre-revenue peers; sector trend toward efficiency amid cash shortages, watch for emulation

Sunshine's 15.2M Series B + new Series C vs Amesite unlisted warrants/Tidewise redemptions; average potential shares inflate 5-10x, pressures post-IPO pops

Sunshine CEO 100% Series B votes highlights control theme in IPOs, absent elsewhere; boosts conviction but risks governance flags in healthcare pipeline

Tidewise clean $10/unit vs mixed ops in others (cash boost/doubt); resurgence theme with faster timelines (Jan 2026 effective), target synergies in AI/biotech

Monitor bid price compliance (> $1.00) post-May 12, 2026 filing; recent volatility signals potential halt, impacts $5M raise success

Track equity raise execution for next 12 months from May 2026; FY end June 30, failure risks bankruptcy vs 17.9% loss progress

Watch $10/unit IPO launch post-Jan 30/31, 2026 effectives; redemption scenarios (25-100%) key for net proceeds in de-SPAC hunt

Series C at $1.03 + excluded Series B $2.07; monitor post-offering exercises for dilution spikes through 2026

Post-Dec 31, 2025 QE visibility into Q1 FY2026 (Sep 2026?); NurseMagic regulatory hurdles, cybersecurity events to flag

Pro forma Oct 31, 2025 scenarios hinge on 15% over-allotment exercise; watch sponsor forfeitures for trust value

$5M general corporate discretion post-Dec 31, 2025 cash; Q2/Q3 2026 updates for biotech pipeline advancement vs burn